InMed Pharmaceuticals Inc.

Climate Impact & Sustainability Data (2023, 2024, 2024-10)

Significant losses and the need to raise additional funds to meet obligations and sustain operations.
Recurring losses and negative cash flows from operations since inception.
Accumulated deficit of approximately $101.4 million at June 30, 2023.
Expected continued operating losses for the foreseeable future.
Market demand for launched compounds not materializing as quickly as anticipated.
Recessionary pressures contributing to hesitation in the health and wellness sector to invest in new rare cannabinoid products.
Perceived competitive advantages not resonating with current product manufacturers.
Downward pricing pressure for cannabinoids in the health and wellness sector.

Seeking additional funding through equity financings, debt financings, or other capital sources, including collaborations, government contracts, or strategic transactions.

Short-term Goals:

Advance INM-901 in ALZ in long-term preclinical in vivo studies and manufacturing
Advance INM-089 in Dry AMD towards IND filing / human clinical trials
Evaluate INM-755 in itch for clinical and commercial partnerships
Target proprietary cannabinoid analogs for pharma R&D pipeline
Supporting BayMedica revenue and margin growth
Identify and execute on strategic partnerships

Short-term Goals:

Advance INM-901 in ALZ in long-term preclinical in vivo studies and manufacturing
Advance INM-089 in Dry AMD towards IND filing / human clinical trials
Evaluate INM-755 in itch for clinical and commercial partnerships
Target proprietary cannabinoid analogs for pharma R&D pipeline
Supporting BayMedica revenue and margin growth
Identify and execute on strategic partnerships